TCGX logo

TCGX

Crunchbase
Pitchbook
Crunchbase

Deals on record

5

Common Fundraising Type

Series B

Aviceda Therapeutics logo
Aviceda Therapeutics

Biotech • Immunomodulators

TCGX logo
Omega Funds logo
Jeito Capital logo
Enavate Sciences logo

Aviceda Therapeutics is a biotech company developing next-generation immunomodulators for ophthalmic conditions using its proprietary HALOS™ nanotechnology platform.

Series C
$207.5M
01/07/2025
Article
Adcendo logo
Adcendo

Biotech • Antibody-Drug Conjugates

TCGX logo
Ysios Capital logo
Venrock Healthcare Capital Partners logo
Surveyor Capital logo

Adcendo is a biotech company focused on developing antibody-drug conjugates for treating cancers with high unmet needs.

Series B
$135M
11/25/2024
Article
Vicebio logo
Vicebio

Biopharmaceutical • Vaccines

TCGX logo
venBio logo
UniQuest logo
Medicxi logo

Vicebio Ltd is a biopharmaceutical company developing next-generation multivalent respiratory virus vaccines using proprietary Molecular Clamp technology.

Series B
$100M
09/23/2024
Article
Candid Therapeutics logo
Candid Therapeutics

Biotechnology • Autoimmune therapies

Venrock Healthcare Capital Partners logo
Vida Ventures logo
TCGX logo
Third Rock Ventures logo

Candid Therapeutics, Inc. is a biotechnology company developing transformative therapies for autoimmune diseases.

Equity
$370M
09/09/2024
Article
Pathalys Pharma logo
Pathalys Pharma

Biopharmaceutical • Clinical trials

TCGX logo
Samsara BioCapital logo
JP Morgan Life Sciences Private Capital logo
Marshall Wace logo

Pathalys Pharma is a biopharmaceutical company developing advanced therapeutics for end-stage kidney disease (ESKD).

Series B
$105M
08/20/2024
Article